THOR Synthorx Inc

PLEASANTON, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the 30th Annual Canaccord Genuity Global Growth Conference on Wednesday, August 11.

David V. Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 4:30 p.m., Eastern Daylight Time (1:30 p.m., Pacific Daylight Time).

The presentation will be available through the conference web site at  http://www.wsw.com/webcast/canaccord2/thor/, or on the company's web site at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System) with more than 15,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. ITC, A-VOX Systems AVOXimeter, HEMOCHRON, ProTime, ProTime InRhythm and IRMA are registered trademarks of International Technidyne Corporation. CentriMag is a registered trademark of Levitronix, LLC.

SOURCE Thoratec Corporation